Literature DB >> 27913436

ERK and p38 MAPK Activities Determine Sensitivity to PI3K/mTOR Inhibition via Regulation of MYC and YAP.

Taru Muranen1, Laura M Selfors1, Julie Hwang1, Lisa L Gallegos1, Jonathan L Coloff1, Carson C Thoreen2,3,4,5, Seong A Kang2,3,4,5, David M Sabatini2,3,4,5, Gordon B Mills6, Joan S Brugge7.   

Abstract

Aberrant activation of the PI3K/mTOR pathway is a common feature of many cancers and an attractive target for therapy, but resistance inevitably evolves as is the case for any cancer cell-targeted therapy. In animal tumor models, chronic inhibition of PI3K/mTOR initially inhibits tumor growth, but over time, tumor cells escape inhibition. In this study, we identified a context-dependent mechanism of escape whereby tumor cells upregulated the proto-oncogene transcriptional regulators c-MYC and YAP1. This mechanism was dependent on both constitutive ERK activity as well as inhibition of the stress kinase p38. Inhibition of p38 relieved proliferation arrest and allowed upregulation of MYC and YAP through stabilization of CREB. These data provide new insights into cellular signaling mechanisms that influence resistance to PI3K/mTOR inhibitors. Furthermore, they suggest that therapies that inactivate YAP or MYC or augment p38 activity could enhance the efficacy of PI3K/mTOR inhibitors. Cancer Res; 76(24); 7168-80. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27913436      PMCID: PMC5161652          DOI: 10.1158/0008-5472.CAN-16-0155

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  56 in total

1.  Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability.

Authors:  R Sears; F Nuckolls; E Haura; Y Taya; K Tamai; J R Nevins
Journal:  Genes Dev       Date:  2000-10-01       Impact factor: 11.361

Review 2.  p38(MAPK): stress responses from molecular mechanisms to therapeutics.

Authors:  Lydia R Coulthard; Danielle E White; Dominic L Jones; Michael F McDermott; Susan A Burchill
Journal:  Trends Mol Med       Date:  2009-08-06       Impact factor: 11.951

3.  The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination.

Authors:  Lydia M Balz; Kai Bartkowiak; Antje Andreas; Klaus Pantel; Bernd Niggemann; Kurt S Zänker; Burkhard H Brandt; Thomas Dittmar
Journal:  J Pathol       Date:  2012-03-21       Impact factor: 7.996

4.  Hepatitis B virus X protein modulates oncogene Yes-associated protein by CREB to promote growth of hepatoma cells.

Authors:  Tao Zhang; Junping Zhang; Xiaona You; Qian Liu; Yumei Du; Yuen Gao; Changliang Shan; Guangyao Kong; Youliang Wang; Xiao Yang; Lihong Ye; Xiaodong Zhang
Journal:  Hepatology       Date:  2012-11-13       Impact factor: 17.425

5.  β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer.

Authors:  Stephan P Tenbaum; Paloma Ordóñez-Morán; Isabel Puig; Irene Chicote; Oriol Arqués; Stefania Landolfi; Yolanda Fernández; José Raúl Herance; Juan D Gispert; Leire Mendizabal; Susana Aguilar; Santiago Ramón y Cajal; Simó Schwartz; Ana Vivancos; Eloy Espín; Santiago Rojas; José Baselga; Josep Tabernero; Alberto Muñoz; Héctor G Palmer
Journal:  Nat Med       Date:  2012-06       Impact factor: 53.440

6.  Cancer cell-derived clusterin modulates the phosphatidylinositol 3'-kinase-Akt pathway through attenuation of insulin-like growth factor 1 during serum deprivation.

Authors:  Hakryul Jo; Yonghui Jia; Kulandayan K Subramanian; Hidenori Hattori; Hongbo R Luo
Journal:  Mol Cell Biol       Date:  2008-05-05       Impact factor: 4.272

7.  Oncogenic mutations of PIK3CA in human cancers.

Authors:  Yardena Samuels; Victor E Velculescu
Journal:  Cell Cycle       Date:  2004-10-12       Impact factor: 4.534

8.  p38 MAPK/MK2-mediated induction of miR-34c following DNA damage prevents Myc-dependent DNA replication.

Authors:  Ian G Cannell; Yi W Kong; Samantha J Johnston; Melissa L Chen; Hilary M Collins; Helen C Dobbyn; Androulla Elia; Theresia R Kress; Martin Dickens; Michael J Clemens; David M Heery; Matthias Gaestel; Martin Eilers; Anne E Willis; Martin Bushell
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-08       Impact factor: 11.205

9.  Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms.

Authors:  Pixu Liu; Hailing Cheng; Stephanie Santiago; Maria Raeder; Fan Zhang; Adam Isabella; Janet Yang; Derek J Semaan; Changzhong Chen; Edward A Fox; Nathanael S Gray; John Monahan; Robert Schlegel; Rameen Beroukhim; Gordon B Mills; Jean J Zhao
Journal:  Nat Med       Date:  2011-08-07       Impact factor: 53.440

10.  Activation of the p38 mitogen-activated protein kinase pathway arrests cell cycle progression and differentiation of immature thymocytes in vivo.

Authors:  N L Diehl; H Enslen; K A Fortner; C Merritt; N Stetson; C Charland; R A Flavell; R J Davis; M Rincón
Journal:  J Exp Med       Date:  2000-01-17       Impact factor: 14.307

View more
  24 in total

Review 1.  YAP/TAZ Signaling and Resistance to Cancer Therapy.

Authors:  Chan D K Nguyen; Chunling Yi
Journal:  Trends Cancer       Date:  2019-03-27

2.  Downregulation of WW domain-containing oxidoreductase leads to tamoxifen-resistance by the inactivation of Hippo signaling.

Authors:  Juan Li; Xuefei Feng; Canyu Li; Jie Liu; Pingping Li; Ruiqi Wang; He Chen; Peijun Liu
Journal:  Exp Biol Med (Maywood)       Date:  2019-06-02

3.  MYCing and YAPing the escape of tumor cell growth arrest after chronic PI3K/mTOR inhibition.

Authors:  Georgios D Vavougios; Sotirios G Zarogiannis
Journal:  J Thorac Dis       Date:  2017-05       Impact factor: 2.895

4.  Prevention of cancer dormancy by Fbxw7 ablation eradicates disseminated tumor cells.

Authors:  Hideyuki Shimizu; Shoichiro Takeishi; Hirokazu Nakatsumi; Keiichi I Nakayama
Journal:  JCI Insight       Date:  2019-02-21

5.  P2Y2 Nucleotide Receptor Prompts Human Cardiac Progenitor Cell Activation by Modulating Hippo Signaling.

Authors:  Farid G Khalafalla; Steven Greene; Hashim Khan; Kelli Ilves; Megan M Monsanto; Roberto Alvarez; Monica Chavarria; Jonathan Nguyen; Benjamin Norman; Walter P Dembitsky; Mark A Sussman
Journal:  Circ Res       Date:  2017-09-18       Impact factor: 17.367

6.  A Novel Notch-YAP Circuit Drives Stemness and Tumorigenesis in Embryonal Rhabdomyosarcoma.

Authors:  Katherine K Slemmons; Lisa E S Crose; Stefan Riedel; Manuela Sushnitha; Brian Belyea; Corinne M Linardic
Journal:  Mol Cancer Res       Date:  2017-09-18       Impact factor: 5.852

7.  NRP-1 interacts with GIPC1 and SYX to activate p38 MAPK signaling and cancer stem cell survival.

Authors:  Daniel Grun; Gautam Adhikary; Richard L Eckert
Journal:  Mol Carcinog       Date:  2018-12-21       Impact factor: 4.784

8.  Co-amplification of phosphoinositide 3-kinase enhancer A and cyclin-dependent kinase 4 triggers glioblastoma progression.

Authors:  Q Qi; S S Kang; S Zhang; C Pham; H Fu; D J Brat; K Ye
Journal:  Oncogene       Date:  2017-04-03       Impact factor: 9.867

9.  CREB promotes laryngeal cancer cell migration via MYCT1/NAT10 axis.

Authors:  Zhao-Xiong Zhang; Wan-Ni Zhang; Yuan-Yuan Sun; Yun-Hui Li; Zhen-Ming Xu; Wei-Neng Fu
Journal:  Onco Targets Ther       Date:  2018-03-08       Impact factor: 4.147

10.  Targeting Multiple Effector Pathways in Pancreatic Ductal Adenocarcinoma with a G-Quadruplex-Binding Small Molecule.

Authors:  Chiara Marchetti; Katherine G Zyner; Stephan A Ohnmacht; Mathew Robson; Shozeb M Haider; Jennifer P Morton; Giovanni Marsico; Tam Vo; Sarah Laughlin-Toth; Ahmed A Ahmed; Gloria Di Vita; Ingrida Pazitna; Mekala Gunaratnam; Rachael J Besser; Ana C G Andrade; Seckou Diocou; Jeremy A Pike; David Tannahill; R Barbara Pedley; T R Jeffry Evans; W David Wilson; Shankar Balasubramanian; Stephen Neidle
Journal:  J Med Chem       Date:  2018-02-07       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.